News | April 25, 2023
Boehringer Ingelheim inaugurates largest European development centre for biotechnology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Bourgoin early development hub broadens offerings for oral solid dose formulations
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
Subscribe To Our Newsletter & Stay Updated
